Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/138971
Author(s): Salehi, B
Selamoglu, Z
Mileski, KS
Pezzani, R
Redaelli, M
Cho, WC
Kobarfard, F
Rajabi, S
Martorell, M
Kumar, P
Martins, N
Santra, TS
Sharifi-Rad, J
Title: Liposomal cytarabine as cancer therapy: From chemistry to medicine
Publisher: MDPI
Issue Date: 2019
Abstract: Cancer is the second leading cause of death worldwide. The main modality to fight against cancer is surgery, radiotherapy, and chemotherapy, and more recently targeted therapy, gene therapy and immunotherapy, which play important roles in treating cancer patients. In the last decades, chemotherapy has been well developed. Nonetheless, administration of the drug is not always successful, as limited drug dosage can reach the tumor cells.. In this context, the possibility to use an encapsulated anti-cancer drug may potentially solve the problem. Liposomal cytarabine is a formulation with pronounced effectiveness in lymphomatous meningitis and reduced cardiotoxicity if compared to liposomal anthracyclines. Thus, the future liposomal cytarabine use could be extended to other diseases given its reduction in cytotoxic side effects compared to the free formulation. This review summarizes the chemistry and biology of liposomal cytarabine, with exploration of its clinical implications.
DOI: 10.3390/biom9120773
URI: https://hdl.handle.net/10216/138971
Source: Biomolecules, vol.9(12):773
Related Information: info:eu-repo/grantAgreement/FCT/5876/147342/PT
Document Type: Artigo em Revista Científica Internacional
Rights: openAccess
License: https://creativecommons.org/licenses/by/4.0/
Appears in Collections:I3S - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
10.3390-biom9120773.pdf1.23 MBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons